A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Academic Thoracic Oncology Medical Investigators Consortium
Study ID
NCT02879617
Phase
PHASE2
Status
Completed

Conditions

  • Non-Small Cell Lung Cancer NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • durvalumab — DRUG
    A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)

Study Details

This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).

Key Dates

Start date
Apr 4, 2017
Status verified
Jan 2024
Primary completion
Jun 4, 2022
Completion
Jun 4, 2022

Study Design

Enrollment
47 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: durvalumab
    1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: Up to 30 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
UPMC Hillman Cancer CenterPittsburghPennsylvania15232-
Simmons Comprehensive Cancer Center - UT Southwestern Medical CenterDallasTexas75390-

Find similar trials in Pittsburgh, PA

By research site
UPMC Hillman Cancer Center· Pittsburgh, PASimmons Comprehensive Cancer Center - UT Southwestern Medical Center· Dallas, TX

Related Studies